204 related articles for article (PubMed ID: 12588776)
1. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia.
Capell WH; DeSouza CA; Poirier P; Bell ML; Stauffer BL; Weil KM; Hernandez TL; Eckel RH
Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):307-13. PubMed ID: 12588776
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia.
Koh KK; Han SH; Quon MJ; Yeal Ahn J; Shin EK
Diabetes Care; 2005 Jun; 28(6):1419-24. PubMed ID: 15920062
[TBL] [Abstract][Full Text] [Related]
3. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
[TBL] [Abstract][Full Text] [Related]
4. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia.
Koh KK; Quon MJ; Shin KC; Lim S; Lee Y; Sakuma I; Lee K; Han SH; Shin EK
Atherosclerosis; 2012 Feb; 220(2):537-44. PubMed ID: 22153696
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction.
Mittermayer F; Schaller G; Pleiner J; Krzyzanowska K; Kapiotis S; Roden M; Wolzt M
J Clin Endocrinol Metab; 2007 Jul; 92(7):2574-80. PubMed ID: 17473072
[TBL] [Abstract][Full Text] [Related]
6. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.
Fabbrini E; Mohammed BS; Korenblat KM; Magkos F; McCrea J; Patterson BW; Klein S
J Clin Endocrinol Metab; 2010 Jun; 95(6):2727-35. PubMed ID: 20371660
[TBL] [Abstract][Full Text] [Related]
7. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.
Rosenson RS; Wolff DA; Huskin AL; Helenowski IB; Rademaker AW
Diabetes Care; 2007 Aug; 30(8):1945-51. PubMed ID: 17483155
[TBL] [Abstract][Full Text] [Related]
8. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
Brisson D; Ledoux K; Bossé Y; St-Pierre J; Julien P; Perron P; Hudson TJ; Vohl MC; Gaudet D
Pharmacogenetics; 2002 Jun; 12(4):313-20. PubMed ID: 12042669
[TBL] [Abstract][Full Text] [Related]
9. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes.
Playford DA; Watts GF; Croft KD; Burke V
Atherosclerosis; 2003 May; 168(1):169-79. PubMed ID: 12732401
[TBL] [Abstract][Full Text] [Related]
10. Resistance vessel endothelial function in healthy humans during transient postprandial hypertriglyceridemia.
Gudmundsson GS; Sinkey CA; Chenard CA; Stumbo PJ; Haynes WG
Am J Cardiol; 2000 Feb; 85(3):381-5. PubMed ID: 11078311
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients.
Hamilton SJ; Chew GT; Davis TM; Watts GF
Clin Sci (Lond); 2010 Feb; 118(10):607-15. PubMed ID: 20047560
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
13. Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability.
Okumura T; Fujioka Y; Morimoto S; Tsuboi S; Masai M; Tsujino T; Ohyanagi M; Iwasaki T
Am J Med Sci; 2002 Nov; 324(5):247-53. PubMed ID: 12449445
[TBL] [Abstract][Full Text] [Related]
14. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.
Genest J; Nguyen NH; Theroux P; Davignon J; Cohn JS
J Cardiovasc Pharmacol; 2000 Jan; 35(1):164-72. PubMed ID: 10630748
[TBL] [Abstract][Full Text] [Related]
15. Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia.
Marchesi S; Lupattelli G; Lombardini R; Roscini AR; Siepi D; Vaudo G; Pirro M; Sinzinger H; Schillaci G; Mannarino E
J Clin Pharm Ther; 2003 Oct; 28(5):419-24. PubMed ID: 14632967
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy.
Rosenson RS; Helenowski IB; Tangney CC
Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):439-47. PubMed ID: 20922563
[TBL] [Abstract][Full Text] [Related]
18. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Kim JA; Lee Y; Shin EK
Diabetes Care; 2006 Feb; 29(2):195-201. PubMed ID: 16443859
[TBL] [Abstract][Full Text] [Related]
19. Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia.
Koh KK; Oh PC; Sakuma I; Lee Y; Han SH; Shin EK
Int J Cardiol; 2016 Oct; 221():342-6. PubMed ID: 27424313
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome.
Rosenson RS; Huskin AL; Wolff DA; Helenowski IB; Rademaker AW
Atherosclerosis; 2008 Jun; 198(2):381-8. PubMed ID: 18242616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
